Cover Image

Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis

Background: The non-steroidal mineralocorticoid receptor antagonists (MRAs) are promising treatments in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). We conducted a meta-analysis to explore the efficacy and safety of the non-steroidal MRAs (finerenone, apararenone, esaxerenon...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xinrui Jiang (Author), Zhengji Zhang (Author), Chunlu Li (Author), Shijin Zhang (Author), Qiang Su (Author), Siyun Yang (Author), Xin Liu (Author), Ying Hu (Author), Xiaofeng Pu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Daiji Kawanami, et al.
Published: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021)

Non-steroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection is a New Option for Patients with Chronic Kidney Disease
by: Wenyu Liu, et al.
Published: (2022)

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
by: Yichuan Wu, et al.
Published: (2022)

Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease
by: Mai Rosenberg, et al.
Published: (2024)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
by: Frédéric Jaisser, et al.
Published: (2021)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
by: Funder JW
Published: (2013)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015)

THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
by: N. T. Vatutin, et al.
Published: (2019)

SM-368229, a Novel Selective and Potent Non-steroidal Mineralocorticoid Receptor Antagonist With Strong Urinary Na+ Excretion Activity
by: Tetsuro Nariai, et al.
Published: (2011)

Pathophysiological Roles of Aldosterone and Mineralocorticoid Receptor in the Kidney
by: Kazi Rafiq, et al.
Published: (2011)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013)

Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
by: Wen-Jun Gou, et al.
Published: (2022)

Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
by: Natalia V. Safronova, et al.
Published: (2022)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019)

Mineralocorticoid receptor blockade for renoprotection
by: Dae Ryong Cha
Published: (2018)

Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure
by: Neven M. Sarhan, et al.
Published: (2020)

Aldosterone-Mineralocorticoid Receptor Cell Biology to Translational Medicine
Published: (2019)

Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
by: Qianlan Chen, et al.
Published: (2024)

Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy
by: Che-Wei Liao, et al.
Published: (2023)

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Pharmacological Effects of Mineralocorticoid-Receptor Blockers
by: Akira Nishiyama, et al.
Published: (2009)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
by: Greg H. Tesch, et al.
Published: (2017)

Pseudohypoaldosteronism in a newborn male with functional polymorphisms in the mineralocorticoid receptor genes
by: Hyun Ah Jeong, et al.
Published: (2015)

Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial
by: Katarzyna Kotfis, et al.
Published: (2022)

Possible Underlying Mechanisms Responsible for Aldosterone and Mineralocorticoid Receptor-Dependent Renal Injury
by: Hideyasu Kiyomoto, et al.
Published: (2008)

A case of pseudohypoaldosteronism type 1 with a mutation in the mineralocorticoid receptor gene
by: Se Eun Lee, et al.
Published: (2011)

Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury
by: Zachary M. Howard, et al.
Published: (2022)

The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice
by: Stefanny M. Figueroa, et al.
Published: (2023)

Effects of 5‐HT₃ receptor antagonists on cisplatin‐induced kidney injury
by: Mitsuhiro Goda, et al.
Published: (2021)

The Dual Dose-Dependent Effects of Corticosterone on Hippocampal Cell Apoptosis After Traumatic Brain Injury Depend on the Activation Ratio of Mineralocorticoid Receptors to Glucocorticoid Receptors
by: Bin Zhang, et al.
Published: (2021)

Azelnidipine Down-Regulates Renal Angiotensin-Converting Enzyme and Mineralocorticoid Receptor mRNA in Diabetic Hypertensive Rats
by: Tetsuya Nakamura, et al.
Published: (2006)

Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor
by: Laura Grohs, et al.
Published: (2023)

Apparent mineralocorticoid excess - A rare cause of endocrine hypertension
by: Sonali Verma, et al.
Published: (2022)

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
by: Tao Xue, et al.
Published: (2023)

Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor
by: Laura Grohs, et al.
Published: (2023)

Baxdrostat and finerenone: new aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system inhibitors for the drug treatment of resistant arterial hypertension
by: O. B. Kuzmin, et al.
Published: (2024)

Efficient and Scalable Enantioselective Synthesis of a Key Intermediate for Rimegepant: An Oral CGRP Receptor Antagonist
by: Zhonghua Luo, et al.
Published: (2024)

Identification of Mineralocorticoid Receptors, Aldosterone, and Its Processing Enzyme CYP11B2 on Parasympathetic and Sympathetic Neurons in Rat Intracardiac Ganglia
by: Lukas Dehe, et al.
Published: (2022)